Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease

Phase 3 Terminated 1457 enrolled Eli Lilly and Company

RandomizedParallel-groupOpen-labelTreatment

Summary

This study is an open-label extension study in Alzheimer's patients who have completed participation in either solanezumab Clinical Trial H8A-MC-LZAM (NCT00905372) or H8A-MC-LZAN (NCT00904683).

Timeline

Start: 2010-12
Primary completion: 2014-07
Completion: 2017-02

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Solanezumab	Protein / enzyme biologic	400 mg	Intravenous

Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease

Summary

Timeline

Drugs

Indications